FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3763205013 | Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3763206014 | Salicylic acid 50 microgram/mg and zinc oxide 200 microgram/mg cutaneous powder | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3661334010 | Salicylic acid+zinc oxide 5%/20% conventional release cutaneous powder (product) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3661335011 | Zinc+salicylic acid dusting powder | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3661336012 | Salicylic acid+zinc oxide 5%/20% conventional release cutaneous powder | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3763205013 | Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3763206014 | Salicylic acid 50 microgram/mg and zinc oxide 200 microgram/mg cutaneous powder | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | Salicylic acid- and zinc oxide-containing product | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has manufactured dose form | Cutaneous powder | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | Product containing salicylic acid in topical dosage form | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Zinc oxide | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Salicylic acid (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | Topical zinc | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | TEMPORARY parent for CDs that are not updated | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator unit | mcg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Count of base of active ingredient | deux | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator value | 50 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator value | 200 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has precise active ingredient | Zinc oxide | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has basis of strength substance (attribute) | Zinc oxide | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has precise active ingredient | Salicylic acid (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength denominator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has concentration strength numerator unit | mcg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Has basis of strength substance (attribute) | Salicylic acid (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Is a | Salicylic acid and zinc oxide only product in cutaneous dose form | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely salicylic acid 50 microgram/1 milligram and zinc oxide 200 microgram/1 milligram conventional release cutaneous powder (clinical drug) | Plays role | Antifungal therapeutic role (role) | false | Inferred relationship | Existential restriction modifier (core metadata concept) |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets